BSX - Abbott's MITRA-FR Potentially Not As Negative As It Appears For Upcoming COAPT Results
Strong Broad-Based Growth; Recent Discussion Focused on MitraClip
Abbott Laboratories (ABT) is a diversified healthcare conglomerate with revenue coming from Medical Devices, Nutrition, Diagnostics, and Established Pharma (generic pharmaceuticals). The stock has performed well as its segments have continued to perform at or above expectations, and the company's recent 2Q results supported this growth trajectory with solid 8% worldwide organic sales growth.
Recent discussion around the stock has focused specifically on MitraClip, the cornerstone of the company's Structural Heart franchise. It's important to remember that the drug is a tiny portion of revenue